retatrutide phase 2 trial results obesity study sees significant weight loss in drug study Retatrutide Results: 24% Weight Loss

Clinical trials have shown that retatrutide, when used in combination with lifestyle modifications and other diabetes medications, can effectively lower HbA1c levelsan important marker of long-term blood sugar control

August 9th, 2025: Lawsuits Mount Over Vision Loss Risks Linked to Ozempic, Wegovy, and Mounjaro New research has suggested a possible connection between GLP-1 receptor agonist drugsincluding Ozempic, Wegovy, and Mounjaroand heightened risks of severe eye conditions such as neovascular age-related macular degeneration (nAMD) and nonarteritic anterior ischemic optic neuropathy (NAION)

Specifically, it may help reduce the risk of heart attacks, strokes, and other heart disease-related events in people who are overweight or have obesity with heart disease

GLP-1 receptors are abundantly expressed in the pancreas, intestine, and central nervous system

CivicScience data indicate people who use Ozempic or other GLP-1 medications consistently report changes in common behaviors, including meals and snack consumption, grocery shopping, dining out, exercising, and more

Sure, it treats the symptoms, at least temporarily